Lantern Pharma (LTRN) investor relations material

Company overview and business model

• Focuses on developing cancer therapies using artificial intelligence to accelerate oncology drug discovery and development, leveraging a proprietary A.I. platform (RADRⓇ) with over 200 billion data points for biomarker-driven drug development.

• Portfolio includes three clinical-stage small molecule oncology candidates (LP-300, LP-184, LP-284), an antibody-drug conjugate program, and a subsidiary for CNS and brain cancer therapies.

• Employs a dual strategy: developing new drug candidates de novo and rescuing previously deprioritized compounds using A.I. and genomics.

• Holds over 200 active patents and patent applications across 20 families, covering drug candidates, biomarker signatures, and patient selection methods.

Financial performance and metrics

• As of March 31, 2026, reported total assets of $7.2 million and working capital of $3.3 million, including $6.3 million in cash, cash equivalents, and marketable securities.

• Closed a $4.4 million gross proceeds offering on May 14, 2026, expected to fund operations until mid-Q1 2027.

• Continues to incur losses and negative operating cash flows, requiring substantial additional funding for ongoing R&D and clinical trials.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive up to $5.1 million if all warrants are exercised for cash.

• Any proceeds from warrant exercises will be used for general corporate purposes.